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In We recently reported that a proto-type thrombopoietin (TPO) receptor agonist, SB-559457, is toxic to acute myeloid leukemia (AML) cell lines and primary AML cells. 1 SB-559457 is a nonpeptidyl, hydrazone class, TPO receptor agonist similar to the Food and Drug Administration approved TPO mimetic, Eltrombopag (E). Here, we confirm that E itself is toxic to AML cell lines and primary AML cells, and initiate studies to understand the drug's mechanism of action in the inhibition of AML cell survival. Myeloproliferative leukemia virus proto-oncogene c-Mpl is the gene encoding TPO-receptor, a member of the hematopoietic growth factor receptor superfamily. TPO and c-Mpl are both necessary for the proliferation and differentiation of megakaryocytes and production of platelets. E also binds to c-Mpl through a defined transmembrane domain, and activates c-Mpl-dependent signaling in cell lines and primary normal CD34 þ stem and progenitor cells. 2 It is hypothesized that these effects are necessary for the clinical activity of E in stimulating platelet production. c-Mpl is expressed in some myeloid leukemia cells, but its function in AML is not defined. Some reports have stated that TPO activates signaling pathways in primary AML cells, but this is not consistently observed. 3, 4 In this paper, we studied the role of c-Mpl in the toxic effects of the hydrazone class of TPO-receptor agonists on AML cells.
First, we tested whether E has a similar effect on AML cell lines as SB-559457 by performing cell growth analysis. Myeloid leukemia cell lines, KCL22, KG1a, HL60, Molm14, K562 and Mo7e, were cultured in their respective optimal culture medium. Cells were seeded into 96-well culture plates and treated with increasing concentrations of E or recombinant human TPO (rhTPO) as a control. The growth curves demonstrated that E inhibited cell proliferation of all tested cell lines in a doseAccepted article preview online 30 October 2012; advance online publication, 27 November 2012 dependent manner (Figure 1a ; representative data are shown). Although the drug sensitivity varied, proliferation of all tested leukemia cell lines were inhibited with 2.5 to 10 mM of E, which is similar to the cell growth inhibition observed with SB-559457. 1 Second, to determine whether E inhibits the growth of primary AML cells, we cultured primary leukemia cells from AML patients without or with E/rhTPO and studied their survival. All tested primary AML samples (n ¼ 14) treated with E show significant decreases in cell number compared with controls ( Figure 1b ; data from a representative patient, sample characteristics provided in Supplementary Table 1) . Our experiments, which were performed in a liquid culture system in the presence of 2% fetal bovine serum, revealed that E at 5 mM concentration was highly toxic to all tested AML samples (n ¼ 14). These data indicate that E inhibits the growth and survival of primary AML cells in addition to AML cell lines. Of note, analysis of caspase and poly(ADP-ribose) polymerase cleavage demonstrated that E induced caspase activation and poly(ADP-ribose) polymerase cleavage, consistent with an apoptotic mechanism of E-induced toxicity, which in turn is consistent with the previously described effects of SB559457 (data not shown). 1 To investigate whether E inhibits the proliferation of myeloid leukemia cells without a correlation to c-Mpl expression, we initially focused on AML cell lines. We studied several myeloid and lymphoid leukemic cell lines, which are not known to express c-Mpl (Jurkat, Ramos, KCL22, KG1a, HL-60, Molm-14 and K562 cells), and one c-Mpl highly expressing megakaryocytic leukemia cell line, Mo7e (Figure 1c, d) . First, we analyzed c-Mpl expression using quantitative real-time PCR (qRT-PCR) and western blot methods. We confirmed that the Mo7e cell line expresses high levels of c-Mpl. To validate relative expression analysis, qRT-PCR was performed using two different reference genes. The qRT-PCR results showed that relative c-Mpl mRNA expression levels in all tested cell lines were less than 1% when compared with that in Mo7e cells (Figure 1a ; data not shown), which suggests that E inhibition of leukemic growth may be independent of c-Mpl expression.
In multipotent hematopoietic progenitor cells, binding of TPO to c-Mpl initiates activation of signaling pathways such as Jak2/ STAT5, Ras/Raf/MAPK and PI3K-Akt signaling pathways, which lead to proliferation and maturation of megakaryocytes and platelet production. [5] [6] [7] [8] [9] [10] [11] [12] To determine whether E activates c-Mpldependent signaling in myeloid leukemia cells, we evaluated phosphorylation of STAT5 by E or rhTPO using Mo7e cells. After 24 h starvation of serum and cytokines, Mo7e cells were stimulated with E (10 mM) or rhTPO (100 ng/ml). Activation of STAT5 by rhTPO peaked between 10 and 20 min (Figure 2a ; data not shown). Interestingly, phosphorylated (p)-STAT5 was not detected in E-treated Mo7e cells. Stimulation tests were also done with lower and higher dose of E (5 and 30 mM), however, no signal of p-STAT5 was detected with either concentration. To investigate whether c-Mpl activation by rhTPO will rescue cells from the E effect, we costimulated Mo7e cells with E and rhTPO simultaneously and determined cell growth and STAT5 activation. Our data demonstrated that the combination of E and rhTPO activated STAT5 to the same level as rhTPO alone (Figure 2a ), but did not rescue the cells from death caused by E (Figure 2b) . Combined, these experiments further demonstrate that the E effect on AML cell survival is independent of c-Mpl signaling.
We also investigated the influence of reduced c-Mpl expression on E's effect in Mo7e cells, which express high levels of c-Mpl. We silenced c-Mpl expression using a lentiviral vector carrying small hairpin RNA (shRNA) directed against c-Mpl and established a stable cell line. Continued expression of the short hairpin construct was tracked using green fluorescent protein, which is coexpressed from this construct. Stably transduced cells containing control or c-Mpl shRNA were green fluorescent protein positive in 82.9% and 97.4%, respectively, as determined by flow cytometry analyses (data not shown). c-Mpl expression levels were analyzed with qRT-PCR and western blot. The qRT-PCR analyses revealed that c-Mpl shRNA-transduced Mo7e (shRNAMo7e) cells expressed 54% less c-Mpl mRNA compared with the control shRNA-transduced Mo7e (control-Mo7e) (data not shown). Western blot analyses showed that c-Mpl protein expression in shRNA-Mo7e was 33.2 ± 4.4% (mean ± s.d.) compared with that in control-Mo7e (Figure 2c ). Using these manipulated Mo7e cells, cell proliferation assays were performed after treatment with E or rhTPO. The cell growth curves demonstrated that proliferation of shRNA-Mo7e cells was inhibited by E to the same extent as in the parental cell line (Figure 2d) . Thus, even in a cell line that endogenously expressed c-Mpl, E inhibition of survival is independent of c-Mpl expression. Because E inhibits leukemic cell line growth, but does not inhibit normal hematopoietic stem cell growth, 2 we questioned whether E might be a general inhibitor of malignant cell growth. Therefore, we assessed the effect of E in other cancer cell lines. First, we performed cell growth assays of E-treated leukemia/ lymphoma cell lines, Jurkat and Ramos cells. Surprisingly, E inhibited cell proliferation of Jurkat and Ramos as well as in myeloid cell lines (data not shown). We also prepared two breast cancer cell lines, MCF7 and T47D, and used the XTT assay (Cell Proliferation Kit II, Roche, Indianapolis, IN, USA) optimal to these adherent cells for drug sensitivity assays. MCF7 and T47D cells were incubated in optimal medium in a 96-well culture plate and the XTT assay was performed 96 h after treatment with E (10, 20 and 30 mM), or with rhTPO (200 ng/ml) as a control. The data were analyzed by calculating the percentage of treated viable cells relative to non-treated viable cells. The XTT assay showed that cell proliferation of Etreated cells was inhibited dose-dependently in both MCF7 and T47D with similar toxicity. In MCF7 cells, the cell proliferation was 63.5±0.98, 46.6±3.10 and 23.0±2.54% (mean ± s.d.) when treated with 10, 20 and 30 mM of E, respectively (data not shown). These results suggest that E may be a general inhibitor of cancer cell growth through a c-Mpl-independent mechanism. According to previous papers reporting pharmacokinetics in healthy volunteers and idiopathic thrombocytopenic purpura patients receiving 75 mg once daily, an approved maximum dose for idiopathic thrombocytopenic purpura patients, the mean maximum plasma concentrations (C max ) were 7.3 and 12.7 mg/ml, 13, 14 which suggests that tested concentrations of E in AML (2.5-10 mM) in this paper are physiologically achievable (10 mM ¼ 5.56 mg per ml free drug).
In summary, we demonstrated that E inhibits myeloid leukemia cell lines regardless of c-Mpl expression. This inhibitory effect was not changed by exogenously added rhTPO or silencing of c-Mpl expression in Mo7e cells. E also inhibits the proliferation of non-AML cell lines such as Jurkat, Ramos, MCF7 and T47D. Taken together, we conclude that E inhibits AML cell proliferation independent of c-Mpl expression. E is a potential drug used for cancer patients under myelosuppresive chemotherapy to support megakaryopoiesis and simultaneously inhibit tumor cell growth. Further interpretation of the mechanism of E's cytotoxic effect on AML cells is now under investigation.
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